Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 3/20 | 0.41 |
| ▸ | HTR1D | P28221 | 2/20 | 0.41 |
| ▸ | HTR1B | P28222 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426861 | 0.87 | SMYD3 (0.43) | SMYD3HTR1AHTR1DHTR1BSLC6A4 | |
| SCHEMBL4091137 | 0.83 | PARP1 (0.49) | SMYD3HTR1AHTR1DHTR1BSLC6A4 | |
| SCHEMBL21419941 | 0.78 | HTR1A (0.43) | SMYD3HTR1AHTR1DHTR1BSLC6A4 | |
| SCHEMBL29954126 | 0.78 | SMYD3 (0.44) | SMYD3HTR1ADRD2PARP1 | |
| SCHEMBL5331739 | 0.78 | SMYD3 (0.44) | SMYD3HTR1ADRD2PARP1 | |
| SCHEMBL3590076 | 0.77 | SMYD3 (0.46) | SMYD3HTR1AHTR1DHTR1BSLC6A4 | |
| SCHEMBL430221 | 0.77 | HTR1A (0.48) | SMYD3HTR1AHTR1DHTR1BSLC6A4 | |
| SCHEMBL19386433 | 0.75 | HTR1A (0.46) | SMYD3HTR1AHTR1DHTR1BSLC6A4 | |
| SCHEMBL428017 | 0.74 | MMP12 (0.40) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL1549777 | 0.73 | HTR1A (0.48) | SMYD3HTR1AHTR1DHTR1BSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED | 2009-03-19 | — | — | US | disclosed |
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | GLAXO GROUP LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| EP-1562917-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004046124-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | XDH, CYP4X1, PDHX | SMYD3 4376/4885HTR1A 47/4885HTR1D 75/4885 |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | XDH, CYP4X1, PDHX | SMYD3 4022/4885HTR1A 476/4885HTR1D 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.